JP5133889B2 - 炎症治療のためのビアリール基置換複素環ｌｔａ４ｈ阻害剤 - Google Patents

炎症治療のためのビアリール基置換複素環ｌｔａ４ｈ阻害剤 Download PDF

Info

Publication number
JP5133889B2
JP5133889B2 JP2008532213A JP2008532213A JP5133889B2 JP 5133889 B2 JP5133889 B2 JP 5133889B2 JP 2008532213 A JP2008532213 A JP 2008532213A JP 2008532213 A JP2008532213 A JP 2008532213A JP 5133889 B2 JP5133889 B2 JP 5133889B2
Authority
JP
Japan
Prior art keywords
group
mmol
substituted
give
pyrrolidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008532213A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009508949A (ja
JP2009508949A5 (enExample
Inventor
ジャスバー シング
ヴィンセント サンダナヤカ
マーク ガーネイ
ペン ユ
ルイス ベデル
ビヨルン ママット
ライ ツァオ
ラマ ケー． ミシュラ
Original Assignee
デコード ジェネティクス イーエイチエフ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デコード ジェネティクス イーエイチエフ filed Critical デコード ジェネティクス イーエイチエフ
Publication of JP2009508949A publication Critical patent/JP2009508949A/ja
Publication of JP2009508949A5 publication Critical patent/JP2009508949A5/ja
Application granted granted Critical
Publication of JP5133889B2 publication Critical patent/JP5133889B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2008532213A 2005-09-21 2006-06-23 炎症治療のためのビアリール基置換複素環ｌｔａ４ｈ阻害剤 Expired - Fee Related JP5133889B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71901605P 2005-09-21 2005-09-21
US60/719,016 2005-09-21
PCT/US2006/024393 WO2007040682A1 (en) 2005-09-21 2006-06-23 Biaryl substituted heterocycle inhibitors of lta4h for treating inflammation

Publications (3)

Publication Number Publication Date
JP2009508949A JP2009508949A (ja) 2009-03-05
JP2009508949A5 JP2009508949A5 (enExample) 2009-08-13
JP5133889B2 true JP5133889B2 (ja) 2013-01-30

Family

ID=37205825

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008532213A Expired - Fee Related JP5133889B2 (ja) 2005-09-21 2006-06-23 炎症治療のためのビアリール基置換複素環ｌｔａ４ｈ阻害剤

Country Status (15)

Country Link
US (3) US7402684B2 (enExample)
EP (1) EP1926708B1 (enExample)
JP (1) JP5133889B2 (enExample)
KR (1) KR101328306B1 (enExample)
CN (1) CN101312948B (enExample)
AU (1) AU2006297798B2 (enExample)
BR (1) BRPI0616187A2 (enExample)
CA (1) CA2623348A1 (enExample)
EA (1) EA017618B1 (enExample)
IL (1) IL190372A0 (enExample)
NO (1) NO20081829L (enExample)
NZ (1) NZ566788A (enExample)
SG (1) SG166769A1 (enExample)
UA (1) UA101943C2 (enExample)
WO (2) WO2007040681A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2634701C (en) * 2005-12-21 2014-07-29 Decode Genetics Ehf Biaryl substituted nitrogen containing heterocycle inhibitors of lta4h for treating inflammation
EP3205644A1 (en) 2005-12-29 2017-08-16 Celtaxsys Inc. Diamine derivatives as inhibitors of leukotriene a4 hydrolase
KR101130380B1 (ko) * 2006-06-13 2012-04-23 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 헤테로시클릭 비뉴클레오시드 화합물, 그의 제조방법, 약학적 조성물 및 항바이러스성 약제로서의 용도
US8115005B2 (en) 2006-08-04 2012-02-14 Decode Genetics Ehf. Pyrazolylphenyl and pyrrolylphenyl inhibitors of LTA4H for treating inflammation
KR101133862B1 (ko) * 2007-07-27 2012-04-06 에프. 호프만-라 로슈 아게 Ｔａａｒ 리간드로서의 2-아제티딘메테인아민 및 2-피롤리딘메테인아민
PE20091017A1 (es) * 2007-10-31 2009-07-16 Janssen Pharmaceutica Nv Diaminas en puente o fusionadas sustituidas con arilo como moduladores de leucotrieno a4 hidrolasa
US20090312558A1 (en) * 2008-06-13 2009-12-17 Reliance Life Sciences Pvt. Ltd. Process for the preparation of arylcyclopropoane carboxylic carbonitriles, and compounds derived therefrom
US20100112606A1 (en) * 2008-10-17 2010-05-06 Michael Armstrong Measurement and analysis of leukotrienes
MX2011012190A (es) * 2009-05-14 2011-12-08 Janssen Pharmaceutica Nv Compuestos con dos porciones de heteroarilo biciclico fusionado como moduladores de la leucotrieno a4 hidrolasa.
WO2011011598A1 (en) 2009-07-24 2011-01-27 Decode Genetics Ehf Process for preparing 4- { (s) -2- (4-(4-chlorophenoxy) phenoxymethyl) pyrrolidin-1-yl) } butyric acid and salts thereof
KR20120101722A (ko) 2009-12-25 2012-09-14 우베 고산 가부시키가이샤 아미노피리딘 화합물
JP2013532734A (ja) 2010-08-04 2013-08-19 ユニバーシティ オブ バージニア パテント ファウンデーション 炎症性疾患を治療するための組成物及び方法
AP3339A (en) 2011-03-14 2015-07-31 Boehringer Ingelheim Int Benzodioxane inhibitors of leukotriene production
US9139567B2 (en) 2011-07-19 2015-09-22 Boehringer Ingelheim International Gmbh Arylpyrazole ethers as inhibitors of leukotriene A4 hydrolase
AR091315A1 (es) 2012-03-06 2015-01-28 Boehringer Ingelheim Int Inhibidores de benzodioxano de la produccion de leucotrieno
JP6080226B2 (ja) 2012-03-06 2017-02-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 他の活性物質と組み合わせたロイコトリエン産生阻害用ベンゾジオキサン
PE20142400A1 (es) * 2012-04-27 2015-02-04 Glaxo Group Ltd Compuestos novedosos
WO2014014874A1 (en) * 2012-07-17 2014-01-23 Boehringer Ingelheim International Gmbh Pyrazole derivatives which inhibit leukotriene production
AU2014249168B2 (en) 2013-03-12 2018-07-12 Celltaxis, Llc Methods of inhibiting leukotriene A4 hydrolase
EP2968265A4 (en) 2013-03-14 2016-12-28 Celtaxsys Inc INHIBITORS OF THE LEUKOTRIEN A4 HYDROLASE
MX2015011678A (es) 2013-03-14 2016-07-08 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
AU2014240042C1 (en) * 2013-03-14 2019-09-05 Celltaxis, Llc Inhibitors of leukotriene A4 hydrolase
WO2015009609A1 (en) 2013-07-15 2015-01-22 Boehringer Ingelheim International Gmbh Inhibitors of leukotriene production
JP2016523982A (ja) * 2013-07-15 2016-08-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成の阻害剤
ES2878405T3 (es) 2014-02-04 2021-11-18 Bioscience Pharma Partners Llc Uso de inhibidores de flap para reducir la lesión mediada por neuroinflamación en el sistema nervioso central
CR20180109A (es) 2015-07-20 2018-05-03 Genzyme Corp Inhibidores de receptor del factor estimulador de colonias 1 (csf-1r)
CN108640864A (zh) * 2018-03-27 2018-10-12 深圳大学 一种查尔酮基荧光探针及其制备方法与应用
EP3801559B1 (en) 2018-05-31 2025-01-01 Celltaxis, LLC Method of reducing pulmonary exacerbations in respiratory disease patients
TWI834581B (zh) * 2018-07-31 2024-03-01 瑞士商諾華公司 Lta4h抑制劑的晶型
MA53433A (fr) * 2018-08-24 2021-06-30 Xeniopro GmbH Éthers phénoxy(hétéro)aryle à activité antiproliférative
CN111100063B (zh) * 2018-10-25 2022-05-17 南京药石科技股份有限公司 一种合成2-氟甲基取代的吡咯烷、哌啶以及哌嗪衍生物的制备方法
CN111620942B (zh) * 2020-06-12 2021-10-15 中国科学院昆明动物研究所 布氏鼠耳蝠白三烯A4水解酶抑制剂Motistin的成熟肽及其应用
CA3221177A1 (en) 2021-11-01 2023-05-04 Meghan Kerrisk Campbell Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68914225D1 (de) * 1988-09-21 1994-05-05 Searle & Co 3-Oxiranbenzoesäuren und Derivate.
IE70521B1 (en) * 1989-02-28 1996-12-11 Zeneca Pharma Sa Heterocycles with inhibitory activity of 5-lipoxygenase
US5149704A (en) * 1991-05-03 1992-09-22 Abbott Laboratories Platelet activating antagonists
GB9226111D0 (en) * 1992-12-15 1993-02-10 Smithkline Beecham Plc Madicaments
GB9411045D0 (en) 1994-06-02 1994-07-20 Smithkline Beecham Plc Compounds and use
US6110944A (en) * 1997-03-12 2000-08-29 G. D. Searle & Co. LTA4, hydrolase inhibitors
US5925654A (en) 1997-03-12 1999-07-20 G.D. Searle & Co. LTA4 , hydrolase inhibitors
CA2298651A1 (en) * 1997-08-07 1999-02-18 Jeffrey Alan Dodge 1-¬4-(substituted alkoxy)benzyl|naphthalene compounds having estrogen inhibitory activity
EP1482931B1 (en) * 2002-03-05 2011-10-19 TransTech Pharma, Inc. Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
US6982259B2 (en) * 2002-04-30 2006-01-03 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
SE0202463D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
WO2005012296A1 (en) * 2003-07-28 2005-02-10 Janssen Pharmaceutica N.V. Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators
WO2006038594A1 (ja) * 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Ｎ型カルシウムチャネル阻害薬

Also Published As

Publication number Publication date
EA017618B1 (ru) 2013-01-30
US8598359B2 (en) 2013-12-03
NO20081829L (no) 2008-06-19
AU2006297798B2 (en) 2013-01-31
UA101943C2 (ru) 2013-05-27
WO2007040681A1 (en) 2007-04-12
NZ566788A (en) 2012-10-26
EP1926708A1 (en) 2008-06-04
JP2009508949A (ja) 2009-03-05
CN101312948B (zh) 2015-01-14
US20070078263A1 (en) 2007-04-05
KR101328306B1 (ko) 2013-11-11
US20070066820A1 (en) 2007-03-22
AU2006297798A1 (en) 2007-04-12
US7402684B2 (en) 2008-07-22
EP1926708B1 (en) 2014-06-18
SG166769A1 (en) 2010-12-29
EA200800865A1 (ru) 2008-12-30
US20090163462A1 (en) 2009-06-25
CN101312948A (zh) 2008-11-26
CA2623348A1 (en) 2007-04-12
IL190372A0 (en) 2009-09-22
WO2007040682A1 (en) 2007-04-12
BRPI0616187A2 (pt) 2011-06-14
KR20080050500A (ko) 2008-06-05

Similar Documents

Publication Publication Date Title
US8598359B2 (en) Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation
KR100848491B1 (ko) 베타아미노기를 갖는 2-싸이아졸리딘 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법
EP1963276B9 (en) N-linked aryl heteroaryl inhibitors of lta4h for treating inflammation
KR101697518B1 (ko) 히스톤 탈아세틸화효소 6 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
IL151533A (en) Cyclic amide derivatives and medicaments and sigma ligands thereof
US20180186739A1 (en) Spiro[cyclobutane-1,3'-indolin]-2'-one derivatives as bromodomain inhibitors
US8680282B2 (en) Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer
JP2001151771A (ja) 含窒素芳香族複素環誘導体
US20080033024A1 (en) Aryl amino acid derivatives as inhibitors for treating inflammation
JP2000344748A (ja) ３−芳香族置換プロピオン酸またはアクリル酸化合物
US8115005B2 (en) Pyrazolylphenyl and pyrrolylphenyl inhibitors of LTA4H for treating inflammation
MX2008004010A (en) Biaryl substituted heterocycle inhibitors of lta4h for treating inflammation
CA2634701C (en) Biaryl substituted nitrogen containing heterocycle inhibitors of lta4h for treating inflammation
US20080090839A1 (en) Phenoxymethylalkyne inhibitors of lta4h for treating inflammation
HK1156947A (en) Alkyl thiazole carbamate derivatives, preparation thereof, and use thereof as faah enzyme inhibitors

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090624

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120313

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120601

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120913

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121009

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121108

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151116

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees